WSJ Tech News Briefing · Monday, August 3, 2026
AstraZeneca and Bristol Myers Squibb reportedly engaged in merger discussions in recent months, according to the Financial Times citing unnamed sources. A potential combination of these two drugmakers could form a pharmaceutical giant with an estimated market value of around $400 billion and annual sales exceeding $100 billion. Both companies declined to comment on the reports.
“Shares in AstraZeneca tumbled while Bristol Myers Squibb stock climbed after reports that the two drugmakers held merger talks.”
“The Financial Times reported that AstraZeneca held discussions with Bristol Myers about a tie-up in recent months, citing unnamed sources.”
“A potential deal between the two companies would create a pharma giant with a combined market value of roughly $400 billion and more than $100 billion in annual sales.”